Related Experiment Video

Updated: Jun 6, 2026

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

Naoko Takebe1, Pamela J Harris, Ronald Q Warren

  • 1National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, EPN7131, 6130 Executive Boulevard, Rockville, Bethesda, MD 20852, USA.

Nature Reviews. Clinical Oncology
|December 15, 2010
PubMed

Insights

Cancer stem cells (CSCs) drive tumor relapse and metastasis by utilizing embryonic signaling pathways. Targeting these pathways and CSCs offers a strategy to improve cancer survival by preventing tumor regrowth.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Tumor relapse and metastasis are significant challenges in cancer treatment, potentially linked to cancer stem cells (CSCs).
  • CSCs possess self-renewal and tumorigenic capabilities, contributing to therapeutic resistance.
  • CSCs rely on conserved stem cell signaling pathways like Wnt, Notch, and Hedgehog (Hh).

Purpose of the Study:

  • To review the role of embryonic signaling pathways in cancer stem cell function.
  • To discuss the development of novel therapeutic agents targeting cancer stem cells.
  • To explore the complexities of signaling cross-talk in cancer stem cell pathways.

Main Methods:

  • Review of existing literature on cancer stem cells and embryonic signaling pathways.
  • Analysis of therapeutic strategies targeting Wnt, Notch, and Hedgehog pathways.
  • Discussion of CSC origins and their contribution to tumor progression.

Main Results:

  • Cancer stem cells utilize key embryonic signaling pathways (Wnt, Notch, Hh) for their survival and function.
  • The origin of CSCs is multifaceted, involving normal stem/progenitor cells or other cancer cells.
  • Targeting CSCs alongside bulk tumor cells may inhibit tumor regrowth.

Conclusions:

  • Embryonic signaling pathways are critical for cancer stem cell activity and therapeutic resistance.
  • Developing targeted anti-CSC therapies requires addressing pathway cross-talk.
  • A combined therapeutic approach targeting both CSCs and bulk tumor cells is promising for improved cancer outcomes.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...